$NVMI

Oppenhaim Eitan sold $750K of NVMI

Oppenhaim Eitan sold 1,290 shares of NOVA LTD. (NVMI) at $581.20 ($0.75M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Oppenhaim Eitan
Published Jun 24, 2026, 6:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 6:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NVMI
Neutral
medium confidence
Mentioned
$NVMI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVMINeutralLow
01

Why it matters

The newest fact is the reported open-market sale (1,290 shares) and the post-sale holdings (6,421 shares), under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure alone is unlikely to drive a major repricing.

03

What to watch

Without context on total insider holdings, prior sale cadence, or whether other insiders also sold/bought, the signal-to-noise for price impact remains low.

Relevance 4/10Novelty 4/10Timing: Filed 2026-06-24; transaction dated 2026-06-22.

Background

The article is an SEC Form 4 insider transaction disclosure for NOVA LTD. (NVMI) by director Oppenhaim Eitan.

Company-level read

Ticker impact

$NVMINeutralMedium confidence
Context

Form 4 shows director Oppenhaim Eitan sold 1,290 NVMI shares in an open-market sale for about $749,748 on 2026-06-22.

Expected impact

Likely limited near-term impact; any effect should be small and short-lived unless followed by additional disclosures.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

No sector-level read-across is provided; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

A large insider sale can still be interpreted as risk-reduction or liquidity needs, but the presence of a pre-arranged 10b5-1 plan weakens that inference.

Key entities

  • NVMI

    NOVA LTD., the issuer of the Form 4 insider transaction.

  • Oppenhaim Eitan

    Director who executed the reported open-market sale under a 10b5-1 plan.

Related articles

$TEVAMed

Wed: Teva jumps but TASE continues to lose ground

Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.

$NVMIMed

Nova WMC™ Expanding Adoption Across the Most Advanced Packaging Processes

Nova (NASDAQ: NVMI) said a leading global foundry customer selected its Nova WMC™ platform as tool-of-record for multi-layer measurement in advanced packaging. The company expects the win to support multiple production flows and notes accelerating WMC™ adoption across memory and foundry customers. Nova cited modular design and nanometer-level large-area scanning throughput.

$TSEMMed

Mon: TASE suffers biggest falls since October 8, 2023

Israel’s Tel Aviv Stock Exchange fell sharply after Iran halted talks with the US over escalation in Lebanon, according to the report. The Tel Aviv 35 Index dropped 4.21% to 4,268.02 and Tel Aviv 125 fell 4.31% to 4,239.39. Turnover was NIS 5.91b in equities and NIS 6.31b in bonds. Tower Semiconductor led losses (-13.99%).